SKY-D is investigating whether ketamine is an effective treatment for young people with depression.
About this study
We are inviting young people aged 16 to 25 years, with moderate-to-severe depression, to take part in this research. Participants will divided into two groups. One group will receive a low dose of ketamine once a week for four weeks. The other group will receive a low dose of another medication, called midazolam, once a week for four weeks.
We hope that the results of this study will help us to provide the best possible care in the future for young people with depression.
Anticipated enrolment close date: 30 November 2023
Contact the SKY-D Research Team for more information.
Who can take part
- Young people aged 16 to 25 years
- Current diagnosis of Major Depressive Disorder
- Treatment with either a stable dose of an antidepressant, or no antidepressant medication, for two or more weeks
- No history of psychosis or bipolar disorder
- No history of a ketamine use disorder of any severity, or presence of a substance use disorder of at least moderate severity within the past six months
- Subcutaneous (under the skin) injections of medication once a week for four weeks
- Interviews and questionnaires
- Blood samples
- Weight and height
- Blood pressure
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.